Detection of IDH1 R132H mutation in acute myeloid leukemia by mutation-specific immunohistochemistry

Applied Immunohistochemistry and Molecular Morphology

Volumn 20, Issue 1, 2012, Pages 37-40

  Byers, Richard ^a,b,c   Hornick, Jason L ^e   Tholouli, Eleni ^d   Kutok, Jeffery ^e   J Rodig, Scott ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute myeloid leukemia; cytogenetics; IDH1 mutation; immunohistochemistry; prognosis

Indexed keywords

ISOCITRATE DEHYDROGENASE (NADP);

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; CYTOGENETICS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MUTATION, MISSENSE;

EID: 83655167157     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e31822c132e     Document Type: Article

References (25)

1. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
2. Dang L, Jin S, Su SM. IDH mutations in glioma and acute myeloid leukemia Trends Mol Med. 2010;16:387-397.
3. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116:2122-2126.
4. Cazzola M. IDH1 and IDH2 mutations in myeloid neoplasms: novel paradigms and clinical implications. Haematologica. 2010;95: 1623-1627.
5. Boissel N, Nibourel O, Renneville A, et al. Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. J Clin Oncol. 2010;28:3717-3723.
6. Chou WC, Hou HA, Chen CY, et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood. 2010;115:2749-2754.
7. Green CL, Evans CM, Hills RK, et al. The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood. 2010;116:2779-2782.
8. Ho PA, Alonzo TA, Kopecky KJ, et al. Molecular alterations of the IDH1 gene in AML: a Childrens Oncology Group and Southwest Oncology Group study. Leukemia. 2010;24:909-913.
9. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:3636-3643.
10. Patel KP, Ravandi F, Ma D, et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011;135:35-45.
11. Schnittger S, Haferlach C, Ulke M, et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood. 2010;116:5486-5496.
12. Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094-1096.
13. Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95:1668-1674.
14. Pardanani A, Lasho TL, Finke CM, et al. IDH1and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia. 2010;24:1146-1151.
15. Zhang Y, Wei H, Wang M, et al. Some novel features of IDH1- mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res. 2011. [Epub ahead of print].
16. Kato Y, Jin G, Kuan CT, et al. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common gliomaderived mutation. Biochem Biophys Res Commun. 2009;390:547-551.
17. Andrulis M, Capper D, Luft T, et al. Detection of isocitrate dehydrogenase 1 mutation R132H in myelodysplastic syndrome by mutation-specific antibody and direct sequencing. Leuk Res. 2010;34:1091-1093.
18. Andrulis M, Capper D, Meyer J, et al. IDH1 R132H mutation is a rare event in myeloproliferative neoplasms as determined by a mutation specific antibody. Haematologica. 2010;95:1797-1798.
19. Mellai M, Piazzi A, Caldera V, et al. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol. 2011. [Epub ahead of print].
20. Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol. 2011;28:115-123.
21. Dias-Santagata D, Akhavanfard S, David SS, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2:146-158.
22. Kaneko MK, Tian W, Takano S, et al. Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun. 2011;406:608-613.
23. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553-567.
24. Reitman ZJ, Parsons DW, Yan H. IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010;17:215-216.
25. Rocquain J, Carbuccia N, Trouplin V, et al. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer. 2010;10:401.